Abstract: The present disclosure provides a method of fabricating a semiconductor device. The method can include bonding a first die and a second die face to face, the first die including a substrate, transistors formed on a face side of the first die over a semiconductor layer with an insulating layer between the substrate and the semiconductor layer, and a first contact structure on the face side of the first die extending through the insulating layer. The method can also include exposing the first contact structure from the back side of the first die, forming, from the back side of the first die, a contact hole in the insulating layer to expose the semiconductor layer, and forming, on the back side of the first die, a first pad-out structure connected with the first contact structure and a second pad-out structure, on the contact hole, conductively connected with the semiconductor layer.

Abstract: Aspects of the disclosure provide a semiconductor device. The semiconductor device includes a first die and a second die boned face-to-face. The first die includes first transistors formed on a face side of the first die in a semiconductor portion and at least a contact structure disposed in an insulating portion outside the semiconductor portion. The second die includes a substrate and second transistors formed on a face side of the second die. Further, the semiconductor device includes a first pad structure disposed on a back side of the first die and the first pad structure is conductively coupled with the contact structure. An end of the contact structure protrudes from the insulating portion into the first pad structure. Further, in some embodiments, the semiconductor device includes a connection structure disposed on the back side of the first die and conductively connected with the semiconductor portion.

Abstract: A semiconductor device is provided. The semiconductor device includes a base layer having a first side for forming memory cells and a second side that is opposite to the first side. The semiconductor device includes a stack of alternating word line layers and insulating layers that is positioned over the first side of the base layer, where the stack includes a first region and a second region. A channel structure extends through the first region of the stack in a vertical direction and further extends into the base layer from the first side. A plurality of connection structures are formed over the second side of the base layer and include a first connection structure that is coupled to the channel structure.

Abstract: Provided is a use of Megamonas funiformis in the prevention and/or treatment of metabolic diseases. Megamonas funiformis has the function of preventing and/or treating metabolic diseases (such as obesity, diabetes, atherosclerosis-related diseases, cardiovascular disease and hvperuricemia).

Abstract: A circuit with a Safe-Torque-Off (STO) functionality and a frequency converter including the same are provided. According to embodiments, the circuit may include a first STO channel configured to control on/off of power supply to a high-side driver of a frequency converter based on a first STO signal, a second STO channel configured to control on/off of power supply to a low-side driver of the frequency converter based on a second STO signal, and a third STO channel configured to control supply of a drive control signal from a controller of the frequency converter to the high-side driver and the low-side driver based on a result of a logical operation of the first STO signal and the second STO signal, wherein the logical operation is configured to make the result active in response to at least one of the first and second STO signals being active.

Abstract: Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: A fabricating method of a semiconductor device is provided. A temporary semiconductor structure is provided. The temporary semiconductor structure includes a temporary substrate and a conductive layer, the temporary substrate has a first surface, the conductive layer is disposed on the first surface of the temporary substrate, and the conductive layer includes one or more first trace. Then, a recess is formed in the temporary semiconductor structure to form a first semiconductor structure and a first substrate. The recess penetrates through the first substrate and expose the one or more first trace. Thereafter, an input/output pad is formed in the recess and on the one or more first trace.

Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Abstract: Provided are a biologically pure Faecalibacterium butyricigenerans strain AF52-21 deposited under CGMCC Accession No. 1.5206 and a composition including the same and a carrier. A method for treating an inflammation-related disease in a subject in need thereof is also provided. The Faecalibacterium butyricigenerans is useful for treating ulcerative colitis and related disorders.

Abstract: Use of Anaerofustis stercorihominis in the prevention and/or treatment of metabolic diseases such as obesity, diabetes, atherosclerosis-related diseases, and cardiovascular diseases.

Abstract: Provided are Megamonas funiformis and applications thereof. Specifically, the Megamonas funiformis has the effects for preventing and/or treating inflammation-related diseases, such as inflammatory bowel diseases (such as ulcerative enteritis, gastritis, and general enteritis) and cardiovascular diseases.

Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.

Abstract: A display device is provided. The display device includes a display screen and an optical film structure arranged on a light exiting side of the display screen. The optical film structure includes a substrate layer and a first micro-lens array layer, where the substrate layer has a first surface and a second surface opposite to each other; the first micro-lens array layer is provided on at least one of the first surface and the second surface, and includes multiple micro-lenses arranged in sequence, each of the multiple micro-lenses has a size smaller than that of a sub-pixel, and edges of adjacent micro-lenses abut on each other.

Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.

Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Abstract: Provided are a composition and the uses thereof. Said composition comprises Megamonas funimormis and/or a metabolite thereof, as well as Anaerofustis stercorihominis and/or a metabolite thereof. Said composition can efficiently treat and prevent inflammation, specifically ulcerative colitis, and related diseases thereof by using a combination of Megamonas funimormis and Anaerofustis stercorihominis, and is safe, efficient, exhibits low toxicity and does not easily produce resistance.

Abstract: The invention provides a catheter positioning device which comprises a base fixed on a body, a positioning guide groove arranged on the base, and a self-locking module positioned on two opposite sides or one side of the positioning guide groove, wherein when the catheter is positioned at a preset position in the positioning guide groove, the self-locking module is in a released state; and when the catheter moves relative to the positioning guide groove to deviate from the preset position, the self-locking module is triggered to switch from the released state to a locking state, so that the self-locking module in locking state limits the movement of the catheter relative to the positioning guide groove so as to achieve the technical effect of positioning the catheter.